VJHemOnc is committed to improving our service to you

COMy 2019 | Consolidation therapy options for myeloma post-transplant

VJHemOnc is committed to improving our service to you

Philip McCarthy

The benefits of consolidation therapy for patients having had hematopoietic stem cell transplantation for multiple myeloma (MM) are still controversial. Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, compares data from the EMN02 (NCT01208766) and BMT CTN 0702 (NCT01109004 ) trials with regards to consolidation therapy. McCarthy highlights that both trials suggest high risk patients may require “something more”, additionally that an ancillary study of BMT CTN 0702 , BMT CTN PRIMeR, aims to understand this further. Secondly, Prof. McCarthy discusses using ixazomib, lenalidomide and daratumumab for maintenance, both individually and in combination. Finally, Prof. McCarthy discusses the importance of defining an early endpoint, this would help drive the field forward in understanding and developing new therapies for MM.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter